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Clinical PerspectiveWhat Is New?The risk of recurrent myocardial infarction originating from a previously untreated lesion, or nonculprit lesion, was more than twice as high as the risk of reinfarction from a previously treated lesion among patients with myocardial infarction who underwent percutaneous coronary intervention.What Are the Clinical Implications?A better understanding of long‐term disease progression and whether reinfarctions occur in previously treated (stented) lesions or in new or progressive lesions may have an impact on decisions on type and duration of medical treatment after an initial myocardial infarction.

Introduction {#jah32830-sec-0009}
============

Globally, an estimated 17.5 million people die annually from cardiovascular disease, of which 7.5 million deaths are attributable to coronary artery disease (CAD).[1](#jah32830-bib-0001){ref-type="ref"}

In developed countries, wider access to new pharmacological therapies and percutaneous coronary intervention (PCI) has substantially reduced mortality after myocardial infarction (MI). Nonetheless, some patients experience subsequent ischemic events. In a large Swedish national register study of almost 100 000 patients with first‐time MI, 18.3% of patients experienced a recurrent MI (re‐MI), stroke, or cardiovascular death during the first year after the index event.[2](#jah32830-bib-0002){ref-type="ref"} Also, of patients who were event free during the first year after MI, 1 in 5 experienced an event during the following 3 years.[2](#jah32830-bib-0002){ref-type="ref"} The risk of recurrent ischemic events has been associated with clinical characteristics, such as age, diabetes mellitus, prior MI, stroke, unstable angina, heart failure, extent of CAD, and the use of revascularization for the index event,[3](#jah32830-bib-0003){ref-type="ref"}, [4](#jah32830-bib-0004){ref-type="ref"}, [5](#jah32830-bib-0005){ref-type="ref"} and also with biomarkers, such as high‐sensitivity troponins, C‐reactive protein, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), and growth differentiation factor‐15.[6](#jah32830-bib-0006){ref-type="ref"}, [7](#jah32830-bib-0007){ref-type="ref"}

Recurrent ischemic events can occur at the original treatment site or in previously untreated lesions that are new or progressive. In the prospective PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study, lesion‐related factors were studied with multimodality imaging in 697 patients.[8](#jah32830-bib-0008){ref-type="ref"} Of the 132 patients (20.4%) who experienced an ischemic event during the follow‐up, approximately half of patients had events related to the nonculprit lesions (NCLs; n=74 \[11.6%\]) and half had events related to the culprit lesion (CL; n=83 \[12.9%\]).

There are limited large population data describing details on the localization (affected vessel/s) and severity (non--ST‐segment--elevation MI or ST‐segment--elevation MI \[STEMI\]) of re‐MIs in relation to the index MI. A better understanding of the clinical predictors for the type of re‐MIs could have implications for treatment decisions after MI and also for the duration of secondary drug‐prevention therapy. We, therefore, sought to evaluate the occurrence of re‐MIs related to the NCL versus the CL and the potential clinical predictors of NCL re‐MIs.

In this study, we provide a large register‐based analysis of re‐MIs and their association with previously treated versus untreated new or progressive lesions.

Methods {#jah32830-sec-0010}
=======

This observational cohort study used prospectively collected data from the SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies) registry and the Swedish National Board of Healthcare registries. This study was approved by the local Ethics Board at Uppsala University (Dnr 2015/241).

Because of data protection principles, the data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Patients {#jah32830-sec-0011}
--------

The national SWEDEHEART registry includes patients with MI from all Swedish hospitals and was started after a merging of the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions, the Swedish Coronary Angiography and Angioplasty Registry, the Swedish Heart Surgery Register, and the National Register of Secondary Prevention After Heart Intensive Care Admissions.[9](#jah32830-bib-0009){ref-type="ref"}, [10](#jah32830-bib-0010){ref-type="ref"}

In this study, patients hospitalized for STEMI or non‐STEMI between July 1, 2006, and November 29, 2014, were included (Figure [1](#jah32830-fig-0001){ref-type="fig"}). Data from SWEDEHEART were merged with data from the National Patient Register for information about hospital admissions. Data linkage was performed by the Swedish National Board of Health and Welfare.

![Patient flow chart. *ICD* indicates *International Classification of Diseases*;MI, myocardial infarction; PCI, percutaneous coronary intervention; and SWEDEHEART, Swedish Web System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies. \*Of these, 661 were invasively evaluated with coronary angiography or fractional flow reserve measurement.](JAH3-7-e007174-g001){#jah32830-fig-0001}

Re‐MI was defined as any rehospitalization after the index MI and registered in the national patient registry or readmission in the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions for MI diagnoses, according to *International Classification of Diseases* codes I21 and I22. Procedural data were captured in the Swedish Coronary Angiography and Angioplasty Registry, which holds data on consecutive patients from all centers that perform coronary angiography and PCI in Sweden. At coronary angiography for any indication, all previously implanted stents are displayed on the report, with information about stent type, stent characteristics, and date and time of implantation and a mandatory question about any occurrence of restenosis or stent thrombosis.

Definitions of CL‐ and NCL‐Related MIs {#jah32830-sec-0012}
--------------------------------------

Patients with *only 1 segment treated* at their primary PCI for the index MI were defined as patients with *CL identified at their index infarction* and included in the NCL/CL analysis (Figure [1](#jah32830-fig-0001){ref-type="fig"}). For the outcome "re‐MI related to CL," the CL needed to be defined at the index MI and treated at the re‐MI. Re‐MIs with \>1 lesion treated were included in the CL definition as long as the originally treated index MI lesion was treated at recurrence. For the outcome "re‐MI related to NCL," the CL needed to be defined at the index MI but not be among lesions treated during the first PCI for the re‐MI.

All captured events of re‐MIs not fulfilling the definitions of re‐MI related to CL or re‐MI related to NCL were defined as "indeterminate re‐MIs" and, thus, excluded from the continued NCL/CL analysis. Indeterminate re‐MIs included MIs with a conservative/noninvasive treatment approach (eg, no coronary angiography performed for the re‐MI) or if coronary angiography was performed for the re‐MI but no PCI.

Statistical Analyses {#jah32830-sec-0013}
--------------------

Continuous variables were expressed as means and SDs, and categorical variables were expressed as percentages. The time‐to‐event curves for re‐MI were calculated using Kaplan‐Meier analysis. The cumulative event proportion of NCL and CL re‐MIs was estimated from cause‐specific Kaplan‐Meier curves, not taking competing risks into account in any other way than censoring if some other type of MI or death occurred. As a sensitivity analysis, a competing risk calculation for cumulative incidences using the approach of Fine and Gray was also performed, treating the other types of MI and death as competing risks.[11](#jah32830-bib-0011){ref-type="ref"} For the analyses of predictors of re‐MIs related to NCL, the study population was limited to those experiencing an re‐MI, defined as either NCL or CL (Figure [1](#jah32830-fig-0001){ref-type="fig"}). A multivariable logistic regression was estimated with preselected predictors of clinical interest: age \>75 years, male sex, smoking, previous PCI, STEMI, impaired kidney function (estimated glomerular filtration rate, \<60 mL/min per 1.73 m^2^), multivessel disease, diabetes mellitus, reduced left ventricular function, and time to re‐MI from the index MI. All reported *P* values are 2‐sided. All analyses were performed with the use of R, version 3.3.2 (R: A Language and Environment for Statistical Computing, R Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2016; <https://www.R-project.org>).

Results {#jah32830-sec-0014}
=======

Re‐MI After the Index Event {#jah32830-sec-0015}
---------------------------

In total, 108 615 patients with first‐occurrence MI (index MI) were identified in SWEDEHEART between July 1, 2006, and November 29, 2014. During a median (interquartile range) follow‐up of 3.2 (1.3--5.6) years, recurrent hospitalization for MIs occurred in 11 117 patients (10.2%) (Figure [2](#jah32830-fig-0002){ref-type="fig"}). The risk of recurrent hospitalizations for MI in patients in whom the CL at the index MI could not be identified was higher than in those in whom the CL was identified (Figure [S1](#jah32830-sup-0001){ref-type="supplementary-material"}).

![Cumulative event probability estimated by the Kaplan‐Meier method, and numbers of patients at risk of recurrent myocardial infarction.](JAH3-7-e007174-g002){#jah32830-fig-0002}

Re‐MIs Related to NCLs and CLs {#jah32830-sec-0016}
------------------------------

Of those who underwent a PCI for the index MI (n=65 976), a CL was identified in 44 332 patients. For these patients, there were a total of 3464 re‐MIs, of which 1243 were related to NCL and 655 were related to CL (Table [1](#jah32830-tbl-0001){ref-type="table-wrap"}). Of the 3464 re‐MIs, 1566 were indeterminate events and could not be classified as NCL or CL re‐MIs. Most of the indeterminate re‐MIs had available SWEDEHEART data (n=1157) but could not be identified as NCL/CL infarctions, because no PCI was performed for the re‐MI (most of these only performed coronary angiography or fractional flow reserve measurement). The remainder (n=409) were not treated in a SWEDEHEART unit or invasively evaluated (Figure [1](#jah32830-fig-0001){ref-type="fig"}).

###### 

Number of Events at 1 and 8 Years and Cumulative Proportion (Estimated by Kaplan‐Meier Censoring for Other Types of MI or End of Follow‐Up) of NCL‐ and CL‐Related Re‐MIs Among Patients With Identified CL (n=44 332) at the Index MI (n=108 615)

  Variable               1 y   8 y                                                                            
  ---------------------- ----- ------- ---------------- --------------------------------------------- ------- ----------------
  Re‐MI related to NCL   504   0.012   0.011 to 0.013   1241[a](#jah32830-note-0003){ref-type="fn"}   0.055   0.051 to 0.059
  Re‐MI related to CL    350   0.009   0.008 to 0.010   655                                           0.028   0.024 to 0.031

CI indicates confidence interval; CL, culprit lesion; MI, myocardial infarction; NCL, non‐CL; and Re‐MI, recurrent MI.

The number of NCL and CL re‐MIs during the full follow‐up of 8.5 years was 1243 and 655, respectively.

Cumulative Proportion at 1 and 8 Years for First Re‐MI Related to NCLs and CLs {#jah32830-sec-0017}
------------------------------------------------------------------------------

There was a higher risk for re‐MIs related to NCL (cumulative proportion, 0.012; 95% confidence interval \[CI\], 0.011--0.013) than CL (cumulative proportion, 0.009; 95% CI, 0.008--0.010) at 1 year (Table [1](#jah32830-tbl-0001){ref-type="table-wrap"}, Figure [3](#jah32830-fig-0003){ref-type="fig"}A). After 8 years' follow‐up, the risk of NCL compared with CL re‐MIs still remained higher: cumulative proportion, 0.06 (95% CI, 0.05--0.09) and 0.03 (95% CI, 0.02--0.03) for NCL and CL, respectively (Table [1](#jah32830-tbl-0001){ref-type="table-wrap"}, Figure [3](#jah32830-fig-0003){ref-type="fig"}B).

![Cumulative proportion calculated with 2 separate cause‐specific hazard functions, censoring if other type of myocardial infarction or end of follow‐up, for first recurrent myocardial infarction within 1 (A) and 8 (B) years related to the nonculprit (n=504 and n=1241 for 1 and 8 years, respectively) and culprit (n=350 and n=655 for 1 and 8 years, respectively) lesions.](JAH3-7-e007174-g003){#jah32830-fig-0003}

A competing risk analysis using the approach of Fine and Gray,^11^ with the other types of MI and death as competing risks, yielded similar results but a slightly lower cumulative incidence: 0.05 (95% CI, 0.04--0.05) and 0.02 (95% CI, 0.02--0.03) for NCL and CL hospitalizations for re‐MIs, respectively (data not shown).

Patient Characteristics at the Index MI for Patients With Recurrent NCL‐ and CL‐Related MI {#jah32830-sec-0018}
------------------------------------------------------------------------------------------

There were small differences in patient characteristics at the index MI for patients subsequently experiencing an NCL versus a CL re‐MI. Patients with NCL re‐MI were more likely to be men (75% versus 68% for NCL versus CL re‐MI) and to have extensive CAD at the index MI than those with CL re‐MI (3‐vessel disease, 18% versus 13% for NCL versus CL re‐MI) (Table [2](#jah32830-tbl-0002){ref-type="table-wrap"}). Furthermore, patients experiencing an NCL re‐MI were more likely to have received a new‐generation drug‐eluting stent during the procedure at the index MI (new‐generation drug‐eluting stent, 69% versus 59% for NCL versus CL re‐MI among those who received a drug‐eluting stent), but there were no large differences between groups in the overall drug‐eluting stent or bare‐metal stent use.

###### 

Baseline Characteristics at the Index Infarction for All Patients With First‐Occurrence MI With the CL Identified and the Subset of Patients With Reinfarctions Related to an NCL and CL

  Variable                                                                          First‐Occurrence MI With Artery Identified (n=44 332)   Re‐MI Related to NCL (n=1243)   Re‐MI Related to CL (n=655)
  --------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------- -----------------------------
  Men                                                                               31 155 (70.3)                                           936 (75.3)                      443 (67.6)
  Age, y                                                                            66±11.7                                                 65.1±11.4                       65.8±11.6
  Body weight, kg                                                                   81.3±15.7                                               82.8±15.7                       80.6±15.7
  Indication for the coronary angiography during hospitalization for the index MI                                                                                           
  ST‐segment--elevation MI                                                          23 446 (53)                                             618 (49.8)                      329 (50.5)
  Non--ST‐segment--elevation MI/unstable angina                                     20 752 (47)                                             624 (50.2)                      323 (49.5)
  Coexisting conditions                                                                                                                                                     
  Hypertension                                                                      18 494 (42.1)                                           596 (48.3)                      300 (46.2)
  Diabetes mellitus                                                                 6314 (14.3)                                             233 (18.8)                      127 (19.5)
  Statin use at hospital admission                                                  7216 (16.4)                                             296 (23.9)                      141 (21.6)
  Smoker status                                                                                                                                                             
  Current                                                                           12 706 (29.2)                                           379 (30.8)                      205 (31.4)
  Former, \>1 mo                                                                    18 899 (32.3)                                           399 (32.4)                      222 (34.0)
  Previous MI                                                                       0 (0)                                                   0 (0)                           0 (0)
  Previous PCI                                                                      1678 (2.6)                                              75 (6.1)                        42 (6.4)
  Previous stroke                                                                   5891 (9.5)                                              70 (5.8)                        40 (6.3)
  Angiographic findings during hospitalization for the index MI                                                                                                             
  1‐Vessel disease (not LM)                                                         26 912 (60.8)                                           494 (39.7)                      373 (57.1)
  2‐Vessel disease (not LM)                                                         10 592 (23.9)                                           479 (38.5)                      164 (25.1)
  3‐Vessel disease (not LM)                                                         5145 (11.6)                                             220 (17.7)                      83 (12.7)
  LM                                                                                1227 (2.8)                                              39 (3.1)                        27 (4.1)
  PCI during hospitalization for the index MI                                                                                                                               
  No. of stents per procedure                                                       1.1±0.6                                                 1.1±0.5                         1.1±0.6
  Drug‐eluting stent                                                                17 947 (43.9)                                           365 (31.6)                      182 (30.0)
  Bare‐metal stent                                                                  23 115 (56.7)                                           798 (69.3)                      429 (71.3)
  Stent diameter, mm                                                                3.1±0.5                                                 3.1±0.5                         3.0±0.5
  Total stent length, mm                                                            21.5±10.8                                               21.5±10.6                       21.6±11.2
  Treated vessel                                                                                                                                                            
  RCA                                                                               14 696 (33.1)                                           441 (35.5)                      216 (33.0)
  LM                                                                                493 (1.1)                                               10 (0.8)                        7 (1.1)
  LAD                                                                               19 856 (44.8)                                           457 (38.6)                      302 (46.1)
  LCX                                                                               9996 (22.5)                                             318 (25.6)                      118 (18.0)
  Lesion severity                                                                                                                                                           
  A                                                                                 4008 (9.0)                                              116 (9.3)                       65 (9.9)
  B1                                                                                16 313 (36.8)                                           446 (35.9)                      204 (31.1)
  B2                                                                                16 375 (36.9)                                           468 (37.7)                      255 (38.9)
  C                                                                                 7495 (16.9)                                             208 (16.7)                      129 (19.7)
  Bifurcation lesion (yes)                                                          3227 (7.3)                                              76 (6.1)                        53 (8.1%)
  Medications at hospital admission for the index MI                                                                                                                        
  ASA                                                                               7996 (18.2)                                             322 (26.0)                      180 (27.6)
  Clopidogrel                                                                       862 (2.0)                                               30 (2.4)                        25 (3.8)
  Ticagrelor                                                                        63 (0.1)                                                4 (0.3)                         2 (0.3)
  Prasugrel                                                                         4 (0)                                                   0 (0)                           1 (0.2)
  Medications during PCI for the index MI                                                                                                                                   
  Glycoprotein IIb/IIIa                                                             10 328 (23.3)                                           382 (30.7)                      205 (31.3)
  Heparin                                                                           30 461 (68.7)                                           822 (66.2)                      453 (69.2)
  LMWH                                                                              1765 (4.0)                                              59 (4.8)                        35 (5.3)
  Bivalirudin                                                                       15 935 (36.0)                                           377 (30.4)                      176 (26.9)
  Medications at hospital discharge for the index MI                                                                                                                        
  ASA                                                                               42 264 (95.8)                                           1195 (96.5)                     628 (96.0)
  Clopidogrel                                                                       30 803 (69.6)                                           1054 (84.9)                     563 (86.0)
  Ticagrelor                                                                        10 412 (23.5)                                           128 (10.3)                      64 (9.8)
  Prasugrel                                                                         1076 (2.4)                                              23 (1.9)                        11 (1.7)
  β Blockers                                                                        40 046 (90.5)                                           1170 (94.2)                     598 (91.3)
  ACE/AT II inhibitors                                                              34 901 (78.9)                                           968 (77.9)                      533 (81.4)
  Calcium antagonists                                                               4910 (11.1)                                             189 (15.2)                      92 (14.0)
  Statins                                                                           41 787 (94.5)                                           1183 (95.2)                     622 (95.0)
  Warfarin                                                                          2176 (4.9)                                              64 (5.2)                        31 (4.7)

Values are number (percentage) or mean±SD. Percentages are computed by group. ACE indicates angiotensin‐converting enzyme; ASA, acetylsalicylic acid; AT, angiotensin; CL, culprit lesion; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main stem; LMWH, low‐molecular‐weight heparin; MI, myocardial infarction; NCL, non‐CL; PCI, percutaneous coronary intervention; RCA, right coronary artery; and Re‐MI, recurrent MI.

The patient characteristics at the index MI of the patients eventually experiencing an re‐MI not classified into NCL/CL (indeterminate MI) are shown in Table [S1](#jah32830-sup-0001){ref-type="supplementary-material"}.

Patient Characteristics at the Re‐MI for Patients With Recurrent NCL‐ and CL‐Related MI {#jah32830-sec-0019}
---------------------------------------------------------------------------------------

NCL re‐MIs were less likely to be STEMIs than CL re‐MIs (STEMI, 25% versus 39% for NCL versus CL re‐MI) (Table [3](#jah32830-tbl-0003){ref-type="table-wrap"}). Stent thrombosis accounted for 22 (3.7%) of the re‐MIs occurring at a CL. At the re‐MI, the complexity of CAD was similar between groups (3‐vessel disease and left main disease, 14% and 4% versus 15% and 4% for NCL and CL re‐MIs, respectively). The angiographic findings at the re‐MI for the patients with indeterminate re‐MIs undergoing angiography are shown in Table [S2](#jah32830-sup-0001){ref-type="supplementary-material"}.

###### 

Patient and Procedural Characteristics at the Re‐MI for Patients With Identified CL at the Index Infarction and NCL or CL Re‐MI

  Variable                                                  Re‐MI Related to NCL (n=1243)   Re‐MI Related to CL (n=655)
  --------------------------------------------------------- ------------------------------- -----------------------------
  Indication for the procedure during the hospitalization                                   
  ST‐segment--elevation MI                                  312 (25.2)                      255 (38.9)
  Non--ST‐segment--elevation MI                             688 (55.5)                      338 (51.6)
  Angiographic findings at the re‐MI                                                        
  1‐Vessel disease (not LM)                                 626 (50.8)                      346 (53.3)
  2‐Vessel disease (not LM)                                 377 (30.6)                      178 (27.4)
  3‐Vessel disease (not LM)                                 174 (14.1)                      96 (14.8)
  Main stem                                                 53 (4.3)                        25 (3.9)
  Definitive stent thrombosis                               23 (1.9)                        24 (3.7)
  PCI for the re‐MI                                                                         
  No. of stents per procedure                               1.4±1.0                         1.2±1.1
  Drug‐eluting stent                                        744 (66.8)                      370 (78.4)
  Bare‐metal stent                                          391 (35.2)                      111 (23.6)
  Stent diameter, mm                                        3.0±0.5                         3.1±0.6
  Total stent length, mm                                    28.6±19.9                       31.6±21.0
  Treated vessel                                                                            
  RCA                                                       425 (34.2)                      229 (35.0)
  LM                                                        38 (3.1)                        15 (2.3)
  LAD                                                       514 (41.4)                      325 (49.6)
  LCX                                                       385 (31.0)                      152 (23.2)
  Lesion severity                                                                           
  A                                                         92 (7.4)                        29 (4.4)
  B1                                                        413 (33.2)                      179 (27.3)
  B2                                                        502 (40.4)                      258 (27.3)
  C                                                         231 (18.6)                      181 (27.6)
  Bifurcation lesion                                        137 (11.0)                      52 (7.9)
  Medication before and under PCI                                                           
  ASA (admission)                                           1186 (95.5)                     625 (95.7)
  Clopidogrel (admission)                                   757 (61.0)                      411 (62.8)
  Ticagrelor (admission)                                    353 (47.8)                      148 (48.5)
  Prasugrel (admission)                                     32 (3.3)                        21 (4.7)
  Glycoprotein IIb/IIIa (during PCI)                        130 (10.5)                      119 (18.2)
  Heparin (during PCI)                                      976 (78.5)                      482 (73.6)
  LMWH (before/during PCI)                                  43 (3.5)                        23 (3.5)
  Bivalirudin (during PCI)                                  351 (28.2)                      204 (31.1)

Values are number (percentage) or mean±SD. ASA indicates acetylsalicylic acid; CL, culprit lesion; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main stem; LMWH, low‐molecular‐weight heparin; MI, myocardial infarction; NCL, non‐CL; PCI, percutaneous coronary intervention; RCA, right coronary artery; and Re‐MI, recurrent MI.

Clinical Correlates With NCL Re‐MI {#jah32830-sec-0020}
----------------------------------

Multivessel disease (odds ratio, 2.29; 95% CI, 1.87--2.82), time to re‐MI (odds ratio, 1.16 years; 95% CI, 1.10--1.22 years), and male sex (odds ratio, 1.36; 95% CI, 1.09--1.71) were identified as factors associated with a higher risk of an NCL re‐MI compared with CL re‐MIs (Figure [4](#jah32830-fig-0004){ref-type="fig"}).

![Multivariable logistic regression model of risk factors for experiencing a nonculprit lesion vs culprit lesion recurrent myocardial infarction during follow‐up in the subset of patients with the culprit lesion identified at index (n=44 332). CI indicates confidence interval; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; and PCI, percutaneous coronary intervention.](JAH3-7-e007174-g004){#jah32830-fig-0004}

Discussion {#jah32830-sec-0021}
==========

In this large cohort of 44 332 patients with first‐occurrence MI with the CL identified during PCI, the risk of re‐MIs not originating from a previously stented lesion was twice as high as the risk of lesions originating from a previously stented lesion. Consequently, although the patients with an MI underwent a PCI for the coronary stenosis believed to need revascularization, most patients, in fact, experienced re‐MIs that did not originate from the treated lesion.

In the PROSPECT study, which prospectively enrolled 697 patients with acute coronary syndrome undergoing coronary angiography and radiofrequency intravascular ultrasonographic imaging after PCI, the cumulative major cardiovascular event rate was 20.4% during the follow‐up of 3.4 years. Major events were almost equally divided between previously untreated and treated lesions.[8](#jah32830-bib-0008){ref-type="ref"} The lower proportion of CL‐related events (CL versus NCL, n=655 versus n=1243) in the current study compared with that observed in the PROSPECT study (CL versus NCL, n=83 versus n=74) could relate to several differences between the 2 studies. In the PROSPECT study, a composite of cardiac events (death from cardiac causes, cardiac arrest, MI, rehospitalization for unstable or progressive angina, revascularization, and stent thrombosis) was assessed for its relation to the CL, where MIs (n=21) constituted only a smaller proportion of the total events (n=132). The current study subclassified a total of 1898 MIs into NCL and CL reinfarctions. Improved stents, improved stenting techniques,[12](#jah32830-bib-0012){ref-type="ref"} and redefined antithrombotic treatment[13](#jah32830-bib-0013){ref-type="ref"}, [14](#jah32830-bib-0014){ref-type="ref"}, [15](#jah32830-bib-0015){ref-type="ref"} for the short‐term phase have had a substantial impact on stent‐related adverse outcomes, but perhaps this impact is less on overall disease progression and the risk of NCL‐related adverse outcomes.[16](#jah32830-bib-0016){ref-type="ref"} Mortality from coronary heart disease has decreased substantially in recent decades. Reductions are attributed approximately half to major risk factor reduction (eg, reduction in cholesterol, systolic blood pressure, and smoking) and half to treatments (eg, initial treatment and revascularization after MI and treatments for heart failure).[17](#jah32830-bib-0017){ref-type="ref"} Unfortunately, the reductions have been counterbalanced by increases in diabetes mellitus prevalence and body mass index.[18](#jah32830-bib-0018){ref-type="ref"} This highlights the importance of long‐term secondary preventive treatment to reduce the overall progression of coronary heart disease.

At the index infarction, no major differences were identified between patients with subsequent NCL compared with CL recurrent infarctions on baseline characteristics. When analyzing clinical factors available for the treating clinician at the index MI, multivessel disease and male sex were associated with a higher likelihood of experiencing an NCL‐related re‐MI. Also, a longer time delay between the index infarction and the re‐MI increased the likelihood of the recurrent infarction being classified as an NCL. The risk of experiencing an NCL versus CL reinfarction at 1 year showed a similar relationship to that after the full 8‐year follow‐up (data not shown). This suggests that the higher risk of NCL reinfarctions was not affected by the unequal higher initial risk, which is coherent with STEMI,[19](#jah32830-bib-0019){ref-type="ref"} the higher risk of procedural MIs early after an index MI, or dual‐antiplatelet treatment usually limited to the first year after MI.[20](#jah32830-bib-0020){ref-type="ref"}

In the PROSPECT study, patients with high‐risk lesions exhibited an overall higher morbidity (by Framingham risk score), more extensive CAD, and a higher likelihood of NCL reinfarctions.[21](#jah32830-bib-0021){ref-type="ref"} Clinical and angiographic characteristics had a poor predictive value for identifying recurrent ischemic events from untreated plaques. The potential of identifying coronary plaque vulnerability with intravascular ultrasonographic imaging laid the groundwork for the ongoing PROSPECT II study (<https://clinicaltrials.gov/ct2/show/NCT03099395?term=NCT03099395&rank=1>), with the aim to establish the utility of intravascular ultrasonographic imaging and near‐infrared spectroscopy to identify plaques prone to future ischemic events. When we evaluated clinical factors possibly associated with type of recurrent infarction, index MI multivessel disease was the strongest predictor of NCL re‐MIs. Although coronary plaque phenotype has been strongly associated with NCL recurrent ischemic events[8](#jah32830-bib-0008){ref-type="ref"}, [22](#jah32830-bib-0022){ref-type="ref"}, [23](#jah32830-bib-0023){ref-type="ref"} and, therefore, suggests a potential clinical benefit of a more extensive and comprehensive characterization of plaques, these techniques are not extensively available in most countries. Information on the extent of CAD or the presence of multivessel disease is readily available from the index MI catheterization and, thus, likely useful for the prediction of reinfarctions not related to the CL.

A better understanding of long‐term disease progression and whether reinfarctions occur in previously treated lesions or in new or progressive lesions may have an impact on decisions on type and duration of medical treatment after an initial MI. Secondary prevention after MI is indicated to prevent the patient from stent‐related adverse events in the short to medium term and also to prevent atherothrombotic events from nontreated lesions long term and overall coronary disease progression.

Limitations {#jah32830-sec-0022}
-----------

Limitations include the observational study design with potential inherent residual confounding. Nonetheless, data used for this report are based on a substantial and large number of variables, with few data missing. The large sample size allows statistical power for multiple candidate variables in the adjusted analyses. The SWEDEHEART quality registry and the national registries of the Swedish Health and Welfare are administrative data sets not primarily established for research purposes and carry some important limitations. The large sample size can potentially be offset by poor quality of the data. Nonetheless, the prospectively enrolled patients admitted to cardiac units in Sweden with symptoms suggestive of an MI and data accuracy are audited by an external monitor annually against source documents (agreement, 96%).[9](#jah32830-bib-0009){ref-type="ref"} The nature of our cohort study and the fact that an invasive strategy was not dictated led to a high proportion of indeterminate MIs. Also, because no angiograms were core laboratory assessed, the definition of NCL and CL was based on information provided on segment level in the Swedish Coronary Angiography and Angioplasty Registry. For the index MI, only MIs in which the CL was treated were considered for further analyses because the Swedish Coronary Angiography and Angioplasty Registry lacks information on operator‐assessed CL.

Conclusions {#jah32830-sec-0023}
===========

In this large observational study of patients after MI, the risk of re‐MIs not originating from a previously stented lesion was twice as high as the risk of lesions originating from a previously stented lesion. Multivessel disease, male sex, and time since the index MI were the strongest predictors of future NCL re‐MIs.
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**Table S1.** Baseline Characteristics at the Index Infarction of Patients With First‐Occurrence Myocardial Infarction With Culprit Lesion Identified and Indeterminate Recurrent Myocardial Infarction During Follow‐Up

**Table S2.** Angiographic Findings in the Subgroup of Patients With Identified Culprit Lesion at the Index Infarction and Indeterminate Recurrent Myocardial Infarction Undergoing Coronary Catheterization

**Figure S1.** Cumulative event probability estimated by the Kaplan--Meier method and numbers of patients at risk of recurrent myocardial infarction in patients with (yes) and without (no) the culprit lesion identified for the index myocardial infarction.
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